AIM: To explore whether intensity modulated radiation therapy (IMRT) in combination with chemotherapy could increase radiation dose to gross tumor volume without severe acute radiation related toxicity by decreasing the dose to the surrounding normal tissue in patients with locally advanced pancreatic cancer. METHODS: Twenty-one patients with locally advanced pancreatic cancer were evaluated in this clinical trial. Patients would receive the dose of IMRT from 21Gy to 30Gy in 7 to 10 fractions within two weeks after conventional radiotherapy of 30Gy in 15 fractions over 3 weeks. The total escalation tumor dose would be 51, 54, 57, 60Gy, respectively. 5-fluororacil (5-FU) or gemcitabine was given concurrently with radiotherapy during the treatment course. RESULTS: Sixteen patients who had completed the radiotherapy plan with doses of 51Gy (3 cases), 54Gy (3 cases), 57Gy (3 cases) and 60Gy (7 cases) were included for evaluation. The median levels of CA19-9 prior to and after radiotherapy were 716 U/ml and 255 U/ml respectively (P<0.001) in 13 patients who demonstrated high levels of CA19-9 before radiotherapy. Fourteen patients who suffered from pain could reduce at least 1/3-1/2 amount of analgesic intake and 5 among these patients got complete relief of pain. Ten patients improved in Karnofsky performance status (KPS). The median follow-up period was 8 months and one-year survival rate was 35%. No patient suffered more than grade III acute toxicities induced by radiotherapy. CONCLUSION: Sixty Gy in 25 fractions over 5 weeks with late course IMRT technique combined with concurrent 5-FU chemotherapy can provide a definitely palliative benefit with tolerable acute radiation related toxicity for patients with advanced pancreatic cancer.
AIM: To explore whether intensity modulated radiation therapy (IMRT) in combination with chemotherapy could increase radiation dose to gross tumor volume without severe acute radiation related toxicity by decreasing the dose to the surrounding normal tissue in patients with locally advanced pancreatic cancer. METHODS: Twenty-one patients with locally advanced pancreatic cancer were evaluated in this clinical trial. Patients would receive the dose of IMRT from 21Gy to 30Gy in 7 to 10 fractions within two weeks after conventional radiotherapy of 30Gy in 15 fractions over 3 weeks. The total escalation tumor dose would be 51, 54, 57, 60Gy, respectively. 5-fluororacil (5-FU) or gemcitabine was given concurrently with radiotherapy during the treatment course. RESULTS: Sixteen patients who had completed the radiotherapy plan with doses of 51Gy (3 cases), 54Gy (3 cases), 57Gy (3 cases) and 60Gy (7 cases) were included for evaluation. The median levels of CA19-9 prior to and after radiotherapy were 716 U/ml and 255 U/ml respectively (P<0.001) in 13 patients who demonstrated high levels of CA19-9 before radiotherapy. Fourteen patients who suffered from pain could reduce at least 1/3-1/2 amount of analgesic intake and 5 among these patients got complete relief of pain. Ten patients improved in Karnofsky performance status (KPS). The median follow-up period was 8 months and one-year survival rate was 35%. No patient suffered more than grade III acute toxicities induced by radiotherapy. CONCLUSION: Sixty Gy in 25 fractions over 5 weeks with late course IMRT technique combined with concurrent 5-FU chemotherapy can provide a definitely palliative benefit with tolerable acute radiation related toxicity for patients with advanced pancreatic cancer.
Authors: Zvi Symon; Mary Davis; Cornelius J McGinn; Mark M Zalupski; Theodore S Lawrence Journal: Int J Radiat Oncol Biol Phys Date: 2002-05-01 Impact factor: 7.038
Authors: G Boz; A De Paoli; R Innocente; C Rossi; G Tosolini; P Pederzoli; R Talamini; M G Trovò Journal: Int J Radiat Oncol Biol Phys Date: 2001-11-01 Impact factor: 7.038
Authors: A Trotti; R Byhardt; J Stetz; C Gwede; B Corn; K Fu; L Gunderson; B McCormick; M Morrisintegral; T Rich; W Shipley; W Curran Journal: Int J Radiat Oncol Biol Phys Date: 2000-04-01 Impact factor: 7.038
Authors: B J Fisher; F E Perera; W Kocha; A Tomiak; M Taylor; M Vincent; G S Bauman Journal: Int J Radiat Oncol Biol Phys Date: 1999-09-01 Impact factor: 7.038
Authors: G V Kornek; R Pötter; E Selzer; A Schratter; H Ulrich-Pur; M Rogy; G Kraus; W Scheithauer Journal: Int J Radiat Oncol Biol Phys Date: 2001-03-01 Impact factor: 7.038
Authors: Howard Safran; Thomas Dipetrillo; David Iannitti; Daniel Quirk; Paul Akerman; Dennis Cruff; William Cioffi; Samir Shah; Nadia Ramdin; Tyvin Rich Journal: Int J Radiat Oncol Biol Phys Date: 2002-09-01 Impact factor: 7.038